FLUIGENT SA

Their core work

Fluigent is a French SME specializing in precision microfluidics — the technology of controlling tiny fluid flows on chip-scale devices. They design and manufacture fluid handling systems used in biomedical research, diagnostics, and lab-on-a-chip applications. Their H2020 work spans from building nanoparticle detection systems for exosome analysis to developing 3D muscle-on-a-chip platforms, positioning them as a key enabler of microfluidic prototyping and production for life science applications.

What they specialise in

How they've shifted over time

Fluigent's early H2020 work (2016-2017) centered on analytical applications — digital detection, exosome isolation, optical biosensing, and interferometry, essentially using microfluidics as a diagnostic and measurement tool. By 2018, their focus shifted toward biological complexity: skeletal muscle tissue, vasculature, neuronal networks, and computational modelling, reflecting the broader organ-on-a-chip trend. This evolution shows a company moving from instrument-level microfluidics toward integrated biological platforms.

Fluigent is moving from pure fluid control hardware toward integrated biological microsystems, making them a strong partner for organ-on-a-chip, in-vitro diagnostics, and tissue engineering projects.

How they like to work

Fluigent operates flexibly — they have coordinated one project (HoliFAB, their largest at EUR 1.37M), participated in two others, and served as a third party in one. With 34 unique consortium partners across 14 countries from just 4 projects, they work in large, diverse consortia rather than small closed teams. This suggests they are comfortable integrating into complex multi-partner research environments while also capable of leading when the project aligns with their core microfluidics competence.

Fluigent has built a broad European network of 34 partners across 14 countries through just 4 projects, indicating they consistently join large consortia with wide geographic spread. Their partnerships span academic groups (single-cell genomics, tissue engineering) and technology developers (biosensing, MEMS manufacturing).

What sets them apart

Fluigent occupies a specific niche: they are a commercial microfluidics company that bridges the gap between lab prototypes and production-ready microfluidic devices. Their coordination of HoliFAB — a pilot line for microfluidic MEMS prototyping — demonstrates they can take research-stage chip designs and move them toward manufacturing. For consortium builders, they bring both the hardware expertise and the commercial perspective needed to turn microfluidic research into usable products.

Highlights from their portfolio

• HoliFAB
  Fluigent's only coordinated project and largest funding (EUR 1.37M), focused on building a pilot production line for microfluidic MEMS — directly aligned with their commercial mission.
• MyoChip
  Represents Fluigent's expansion into organ-on-a-chip territory, building 3D innervated muscle tissue with vasculature — a high-growth application area for their core technology.
• INDEX
  Demonstrates Fluigent's capability in integrated biosensing, combining microfluidics with optical detection and magnetic immunocapturing for exosome analysis.